Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1987-11-18
1989-10-31
Schain, Howard E.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
20415768, 422 24, 424 858, 424101, A61K 39395, A61K 4100
Patent
active
048778664
ABSTRACT:
A method of producing a virus-safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation. The object is to make the method appropriate for industrial-scale production and economical by means of the enrichment and multistage purification of a plasma that has had the coagulation factors removed from it or of a plasma fraction or serum fraction that contains immunoglobulin G accompanied by treatment with ion exchangers and by ultrafiltration. The precipitant is eliminated, by means of diafiltration or gelfiltration, either from the plasma that has had the coagulation factors removed from it or from the plasma fraction that contains the immunoglobulin G, and the desired ion composition is established. The resulting protein solution is subjected to fractionation over an ion exchanger to separate the immunoglobulin G. The proteolytic enzymes in the resulting immunoglobulin-G solution are removed by means of affinity chromatography over a dye linked sorbent and/or are ihibited by the addition of antithrombin III. The accordingly stabilized immunoglobulin-G solution is treated, at a protein concentration of 20 to 60 g/l and a pH 6.0 to 8.0, with 0.03 to 0.07% of .beta.-propiolactone, diluted to a protein concentration of 5 to 20 g/l and subjected to ultraviolet radiation. The accordingly sterilized dilute immunoglobulin-G solution is again diafiltered or gelfiltered to remove lower molecular-weight substances. The accordingly stabilized and sterilized solution is adjusted to the desired protein content of 2 to 16% and filtered sterile.
REFERENCES:
patent: 2710293 (1955-06-01), Gerlough
patent: 2710294 (1955-06-01), Gerlough
patent: 3916026 (1975-10-01), Stephan
patent: 3984539 (1976-10-01), Khouw et al.
patent: 4136094 (1979-01-01), Condie
patent: 4305870 (1981-12-01), Liu et al.
patent: 4318902 (1982-03-01), Stephan
patent: 4322403 (1982-03-01), Bunnig
patent: 4388232 (1983-06-01), Eibl et al.
patent: 4482483 (1984-11-01), Curry et al.
patent: 4639513 (1987-01-01), Hou et al.
Dichtelmuller Herbert
Kothe Norbert
Piechaczek Detlef
Rudnick Dieter
Schleussner Hans
Biotest Pharma GmbH
Schain Howard E.
LandOfFree
Method of producing a virus safe, storage-stable, and intravenou does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of producing a virus safe, storage-stable, and intravenou, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of producing a virus safe, storage-stable, and intravenou will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-626789